PER® Miami Breast Cancer Conference | Conference

Breast Surgeons Essential for Effective Genetic Testing

March 10th 2017

It is imperative that surgeons remain involved in genetic counseling to meet the immense unmet need that exists for patients with breast cancer, given a shortage of available genetic counselors.

Dr. Chagpar on Novel Agents for Neoadjuvant TNBC Treatment

March 10th 2017

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.

Ribociclib Effective in Elderly Patients With HR+/HER2- Breast Cancer

March 10th 2017

Adding ribociclib to frontline letrozole reduced the risk of disease progression or death by 40% in elderly patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to a subgroup analysis of the phase III MONALEESA-2 trial presented at the 34th Annual Miami Breast Cancer Conference.

Dr. Jahanzeb on the APHINITY and ExteNET Trials in Breast Cancer

March 10th 2017

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the APHINITY and ExteNET studies in breast cancer.

Eribulin/Pembrolizumab Combo Effective for TNBC

March 10th 2017

The combination of eribulin and pembrolizumab demonstrated promising objective response rates, including a complete response, for patients with metastatic triple-negative breast cancer.

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast Cancer

March 10th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Dr. Dixon on Prevalence and Risk Factors of Male Breast Cancer

August 10th 2016

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

Dr. Lehman on 3D Mammography in Screening for Breast Cancer

August 8th 2016

Constance D. Lehman, MD, PhD, professor of radiology and chief of Breast Imaging in the Department of Radiology at Massachusetts General Hospital, discusses how 3D mammography has been an efficient and beneficial screening tool in the field of breast cancer.

Dr. Kuerer on Challenges With Treating DCIS

June 30th 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

Dr. Chagpar on Surgical Treatment of Patients With HER2+ Breast Cancer

June 29th 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology) and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses how surgical oncologists should approach the treatment of a patient with HER2-positive breast cancer.

Dr. Partridge on PGD in Young Patients With Breast Cancer

April 28th 2016

Ann H. Partridge, MD, MPH, founder and director, Program for Young Women with Breast Cancer, director, Adult Survivorship Program, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses preimplantation genetic diagnosis (PGD) in young patients with breast cancer.

Dr. Seidman on Ixabepilone in Patients With Aggressive Breast Cancer

March 18th 2016

Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Mittendorf Explains What's New With NeuVax in Breast Cancer

March 14th 2016

Elizabeth A. Mittendorf, MD, PhD, discusses nelipepimut-S (NeuVax), a peptide derived from HER2 protein combined with granulocyte-macrophage colonystimulating factor that is currently being investigated as a single-agent, in combination with standard-of-care therapies, and in multiple settings and subtypes of breast cancer.

Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

March 13th 2016

Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

Dr. Tripathy on Ixabepilone in Patients With TNBC

March 13th 2016

Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Genomic Profiling of DCIS Is Ready for Prime Time

March 13th 2016

There is a subset of low-risk patients with ductal carcinoma in situ for whom surgery alone is optimal and the Oncotype DX DCIS Score is a useful assay for identifying these individuals.

Tripathy Reviews Pivotal Breast Cancer Presentations

March 13th 2016

A number of crucial findings were presented over the course of 2015 that helped to characterize an ever-growing trend toward personalized medicine in the treatment of breast cancer.

Despite Setbacks, pCR Still Acceptable for Breast Cancer Approvals

March 13th 2016

Pathologic complete response may still have a role in accelerated neoadjuvant approvals for select patients with early stage breast cancer, despite the fact that it remains an unproven surrogate endpoint.

Dr. Verma on Advancements in Treatment of HER2-Positive Breast Cancer

March 12th 2016

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.

Amy Robach on Factors Impacting Her Breast Cancer Treatment Decision

March 12th 2016

Amy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.